Who are Drug either PPIS or H2RA and prokinetics's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drug-either-ppis-or-h2ra-and-prokinetics.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-21 · How we verify

Drug either PPIS or H2RA and prokinetics — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug either PPIS or H2RA and prokinetics (Drug either PPIS or H2RA and prokinetics) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antacid and prokinetic agent. Area: Gastroenterology.

marketed Combination antacid and prokinetic agent H+/K+-ATPase (PPIs) or H2 receptor (H2RAs); dopamine antagonist or other prokinetic target Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Drug either PPIS or H2RA and prokinetics (Drug either PPIS or H2RA and prokinetics) — King Saud University. This is a combination therapy using either proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) to reduce gastric acid, paired with prokinetic agents to enhance gastric motility and accelerate gastric emptying.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Drug either PPIS or H2RA and prokinetics TARGET	Drug either PPIS or H2RA and prokinetics	King Saud University	marketed	Combination antacid and prokinetic agent	H+/K+-ATPase (PPIs) or H2 receptor (H2RAs); dopamine antagonist or other prokinetic target

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antacid and prokinetic agent class)

King Saud University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Drug either PPIS or H2RA and prokinetics — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-either-ppis-or-h2ra-and-prokinetics. Accessed 2026-05-21.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab